# Synthesis, Structural Characterization, and In Silico Evaluation of the Salicylidene Schiff Base 4‑{(E)‑[(2,3-Dihydroxyphenyl)methylidene]amino}-2-hydroxybenzoic Acid as a Promising Scaffold for Human Transthyretin Inhibitor

## TL;DR

A new salicylidene compound was synthesized and shown to potentially inhibit human transthyretin, with good absorption and low toxicity.

## Contribution

The compound's zwitterionic structure and potential as a transthyretin inhibitor scaffold are newly characterized.

## Key findings

- The compound crystallizes in the triclinic P1̅ space group with a zwitterionic keto form.
- In silico studies suggest high gastrointestinal absorption and low toxicity.
- The compound shows binding affinity comparable to Tolcapone as a TTR inhibitor.

## Abstract

The Schiff base derived from the condensation of 4-aminosalicylic
acid with 2,3-dihydroxybenzaldehyde was synthesized and characterized
by using experimental techniques, theoretical calculations, and in
silico methods. Single-crystal X-ray diffraction analysis showed that
the compound crystallizes in the triclinic P1̅
space group with two molecules in the asymmetric unit, both adopting
a zwitterionic keto form. In silico studies predict high gastrointestinal
absorption, low toxicity, and potential activity as a transthyretin
(TTR) inhibitor, with binding affinity comparable to that of the drug
Tolcapone, suggesting that the synthesized compound may be a promising
scaffold for a TTR stabilizer.